ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
Results from the international phase 3 AMPLTUDE clinical trial found that adding niraparib to abiraterone…
Browsing: ASCO
ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, and most patients…
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer
The results of an international phase 3 clinical trial sponsored by the National Cancer Institute,…
ASCO 2025: Rusfertide shows promise for polycythemia vera treatment
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
ASCO 2025: Switch to camizestrant after liquid biopsy detection of breast cancer recurrence improves outcomes
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…
ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…
ASCO 2025: Zanidatamab plus chemotherapy shows strong first-line efficacy in HER2-positive gastro-oesophageal adenocarcinoma
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
ASCO 2025: ARCHES and Australian-led ENZAMET prostate cancer trials to present XTANDI® (enzalutamide) data
New data, to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting…